A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)

Study Coordinator: Juan Morales Viera

Status: Enrolling

ClinicalTrials.gov Number: NCT03947255

Phone: 786.803.2333

Protocol Number: PRO00025435


This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.
More to Explore